Top 50 Ai For Drug Discovery in Europe

This startup provides an AI-powered drug discovery platform that accelerates early-stage research by offering a screening and scoring tool. This platform helps pharmaceutical companies reduce the time and resources needed to identify and develop new drug candidates.

Oxford Drug Design offers an AI‑powered platform that combines deep aaRS biology with proprietary algorithms such as EShape™ and SynthAI™ to perform ligand‑ and structure‑based virtual screening of a 6 M purchasable compound library. The workflow generates synthetically tractable candidates, ranks them with interpretable ML models via AIScape™, and delivers hit‑to‑lead optimization for pharmaceutical, biotech, and academic programs targeting oncology, infectious disease, and other high‑need areas.

The startup develops a drug discovery platform that combines artificial intelligence and synthetic biology to digitize natural diversity and identify potential drug candidates based on their functions. This approach aims to make the discovery of new therapeutics for cancer, metabolic diseases, and infectious diseases more predictable and cost-effective.

Totus Medicines utilizes AI/ML and DNA-encoded covalent library technology to discover small molecule drugs targeting previously undruggable disease pathways. Their platform enables high-throughput drug discovery, significantly increasing the speed and efficiency of developing therapeutics for advanced cancers and other serious conditions.

Causaly is a generative AI platform that automates knowledge extraction from vast biomedical literature, enabling researchers to identify validated targets and novel biomarkers with high precision. By reducing research time from months to minutes, it enhances productivity by up to 90%, allowing scientists to focus on innovative drug discovery.

NEBULA utilizes dataset-free generative AI and physics-based modeling to create detailed 3D maps of macromolecules, facilitating the identification of potential drug targets. This technology enhances the drug discovery process by providing precise structural insights that are essential for developing new pharmaceuticals.

The startup has developed an artificial intelligence platform that predicts molecular properties and target affinity using structured perception and feature fusion techniques. This technology streamlines data analysis workflows for biopharma research teams, enabling them to conduct fewer experiments while improving drug discovery outcomes.

SilicoGene offers a no-code platform for health-tech teams to manage the entire AI lifecycle in drug discovery, enabling users to prepare bioinformatics data, train models, and deploy them efficiently. The platform provides on-demand access to cost-effective GPUs and ensures data security through HIPAA-compliant infrastructure, facilitating rapid deployment of AI solutions in real-world applications.

Kuano's discovery platform integrates quantum mapping and AI-driven chemistry to enhance the design of enzyme inhibitors, significantly improving candidate quality and reducing development time. By addressing inefficiencies in drug discovery, Kuano enables pharmaceutical and biotech companies to identify superior starting points for drug candidates more rapidly.

Abzu utilizes its proprietary explainable AI technology, the QLattice®, to analyze complex datasets in pharmaceutical research, providing transparent insights that enhance drug discovery and development. By delivering clear and interpretable models, Abzu addresses the challenge of opaque AI systems, enabling researchers to understand the underlying factors driving their data-driven decisions.

Healx utilizes generative AI to enhance and combine existing compounds for the rapid discovery of treatments for rare diseases, addressing the lack of effective therapies for over 90% of the 10,000 known rare diseases. By de-risking the drug development process, Healx increases the likelihood of successful outcomes and accelerates the delivery of new therapies to patients.

Ingenix provides a multimodal generative AI platform that builds digital twins of drug candidates by integrating genomics, proteomics, imaging, literature, and electronic health records across molecular to population scales. The system delivers detailed, interpretable predictions of clinical efficacy, safety endpoints, and adverse events, and supports natural‑language “what‑if” queries for trial design and candidate prioritization. It is aimed at pre‑clinical, strategic R&D, and clinical development teams in pharmaceutical and biotechnology companies.

Turbine's Simulated Cell™ platform utilizes AI to predict biological responses by simulating experiments across various models, including engineered cell lines and patient samples. This technology accelerates drug development by generating actionable insights in half the time of traditional methods, enabling researchers to identify optimal experimental pathways for novel cancer therapies.

Healx provides an AI‑powered platform that integrates genomics, phenotypic and clinical data to identify and prioritize repurposed or optimized compounds for rare disease indications. The system automates in silico screening, predictive efficacy and safety modeling, and workflow orchestration to move candidates from computational prediction to preclinical validation, lowering discovery costs and timelines. It is offered to pharmaceutical, biotech and research consortium partners seeking to expand rare‑disease pipelines.

The startup specializes in Pharma 3.0 drug discovery, utilizing advanced computational methods and machine learning algorithms to identify potential drug candidates more efficiently. This approach addresses the high costs and lengthy timelines associated with traditional pharmaceutical research and development.

XtalPi is a pharmaceutical technology company that utilizes computational modeling and machine learning to predict drug interactions and properties, followed by experimental validation in wet labs. This approach reduces the time and cost associated with traditional drug discovery processes, enabling faster development of effective therapeutics.

Nabla Bio utilizes biologically informed machine learning and experimental technologies to design antibodies with atomic precision, targeting complex disease mechanisms such as GPCRs and ion channels. The platform enhances drug manufacturability, safety, and efficacy by integrating AI-driven design with empirical measurement of human-relevant drug properties.

PentaBind utilizes generative AI to design aptamers that can selectively target and bind to specific molecules, addressing the limitations of traditional wet-laboratory methods in therapeutic development. This technology enables the creation of highly effective aptamer drugs that are smaller, more selective, and capable of penetrating tumors, significantly improving the precision of cancer treatments.

The startup is developing a proprietary artificial intelligence platform for creating patient-level models of autoimmune diseases, aimed at enhancing the drug discovery process in immunology and inflammation. This technology enables more precise targeting of treatments, improving patient outcomes in the management of autoimmune conditions.

HeartBeat.bio is developing a high-throughput 3D screening platform that utilizes human organoid technologies and artificial intelligence to enhance cardiac drug discovery. This approach addresses the inefficiencies in traditional drug development methods by providing more accurate and relevant biological models for testing potential therapies.

Antiverse utilizes machine learning and advanced cell line engineering to design target-specific antibody libraries for challenging drug targets, including G-protein coupled receptors and ion channels. The platform accelerates the antibody discovery process, enabling the development of functional therapeutics within six months, addressing the lengthy timelines typically associated with traditional drug development methods.

CHARM Therapeutics utilizes its proprietary DragonFold technology, which employs 3D deep learning for protein-ligand co-folding, to develop small molecule inhibitors targeting previously undruggable proteins associated with cancer and other diseases. By addressing the challenge of the vast majority of the human proteome remaining undruggable, the company aims to create transformative therapies for patients with high unmet medical needs.

Sable Bio utilizes artificial intelligence to analyze extensive biomedical data for assessing drug target safety, providing quantified risk evaluations and recommended mitigations. The platform addresses the challenges of incomplete and outdated safety information, enabling more efficient and informed decision-making in drug development.

Metaphore Biotechnologies utilizes its MIMiC platform, which combines machine learning with molecular mimicry, to design therapeutics that enhance function, specificity, and selectivity for challenging drug targets. The company aims to create transformative treatments that outperform existing drugs, improving patient outcomes in areas like obesity management.

Kvantify develops a computational drug discovery platform that utilizes proprietary physics-based methods and bespoke algorithms to enhance the quality of compound screening for biotech and pharmaceutical companies. By integrating classical and quantum computing techniques, the platform accelerates research processes and reduces the risks associated with drug development.

The startup develops clinically validated software applications that utilize artificial intelligence to analyze real-world data, enhancing patient outcomes and supporting the discovery of new medicines. By connecting patients, clinicians, and researchers, the platform generates extensive phenotypic databases that enable discovery research companies to maximize revenue in the healthcare sector.

PolyModels Hub provides ModelFlow, a digital platform that utilizes AI-driven modeling and simulation to streamline pharmaceutical process development from initial design to product launch. This solution enables scientists to optimize experimental designs, enhance data extraction, and accelerate decision-making, ultimately reducing time-to-market for drug products.

Parallel Bio utilizes immune organoids and artificial intelligence to design immunotherapies that are tested in human-like environments, eliminating the reliance on animal models. This approach significantly reduces the time and cost of drug development, increasing the likelihood that new therapies reach patients effectively and safely.

Phenaros utilizes phenomics and AI-driven cell morphological profiling to accelerate drug discovery for rare diseases by automating data collection and experimentation. The company addresses the challenge of limited high-quality data in drug development, enabling faster and more efficient identification of new and repurposed therapeutics.

CoSyne Therapeutics utilizes polymathic AI and genetic computational systems analysis to expedite the development of pharmaceuticals targeting high-risk brain cancer. By digitizing cellular responses, the company enables medical researchers to create a new class of drugs more efficiently and at a lower cost than traditional methods.

NETRI develops human cell-based assays and organs-on-chip technologies that utilize neurons as biosensors to evaluate acute and chronic responses in pharmaceutical research. By providing high-throughput electrophysiological recording and AI-driven predictive analytics, NETRI enhances drug discovery and preclinical testing across various therapeutic areas, including oncology and neurological disorders.

Vincere Biosciences develops novel therapeutics targeting Parkinson's disease and age-related kidney disease, utilizing proprietary AI/ML tools to design and optimize drug candidates. Backed by over $2.7 million in grants from organizations like the NIH and the Michael J. Fox Foundation, the company aims to initiate human trials for its first molecule within 18 months.

The startup develops analytics software that integrates multi-omic data with AI analytics to enhance drug candidate identification and biomarker discovery. This technology enables precision medicine organizations to streamline research processes and significantly reduce time-to-market for new treatments.

BioStrand utilizes its patented LENSai™ Integrated Intelligence Technology to analyze multi-omics data and accelerate antibody drug discovery through advanced computational methods. This technology addresses the inefficiencies in identifying and prioritizing lead drug candidates by providing rapid insights into drug interactions and predicted efficacy.

Nested Therapeutics utilizes a proprietary drug discovery platform that employs genomics, computational biophysics, and machine learning to identify novel driver mutations and druggable pockets in cancer pathways. This approach addresses the challenge of developing targeted therapies for the vast majority of recurrent cancer-associated mutations that currently lack FDA-approved treatments.

TwinEdge Bioscience provides a cloud‑based platform that creates high‑fidelity digital twins of individual patient tumors by integrating genomics, transcriptomics, proteomics and histopathology data. Its AI‑augmented simulation engine predicts drug response, resistance mechanisms and biomarker associations across a library of over 10,000 validated tumor avatars, enabling pharmaceutical and CRO teams to prioritize candidates, design trials and stratify patients before human enrollment.

ALLOX utilizes systematic mutagenesis, high-throughput phenotyping, and biophysical modeling to identify allosteric switches in proteins, enabling the rapid development of novel therapeutics for human diseases. By harnessing genetics and AI, the company addresses the challenge of predicting and engineering protein functions, aiming to transform drug discovery and biotechnology.

BioStrand accelerates biotherapeutic discovery with its LENS ai™ platform, a SaaS solution that integrates multi-omics, textual, and structural data. Leveraging proprietary HYFTs® technology and advanced AI, including protein language models and vector search, the platform provides actionable insights to streamline target identification and optimize the drug discovery process.

Provides an AI-powered platform for analyzing complex medical data, including transcriptomics, epigenomics, and proteomics, using modular machine learning techniques. This system accelerates research by delivering fast, high-quality insights for identifying therapeutic targets, biomarkers, and disease mechanisms, reducing time and cost compared to traditional methods.

Poolbeg Pharma is a biopharmaceutical company focused on developing treatments for infectious diseases and metabolic conditions, utilizing artificial intelligence to enhance drug discovery efficiency. The company addresses the critical unmet medical needs in areas such as cancer immunotherapy-induced cytokine release syndrome and obesity through its robust pipeline of clinical assets.

ScienTek accelerates aptamer discovery for challenging protein targets using an AI-powered platform. Their technology combines in silico screening with in vitro validation to identify and optimize nucleic acid sequences with high binding affinity for next-generation therapeutics.

Deepflare develops a silico antigen discovery platform that utilizes machine learning algorithms to analyze genomic data and identify neoantigens for personalized cancer therapies. This technology enhances immunogenicity modeling and streamlines the drug development process, reducing costs and improving treatment outcomes for pharmaceutical companies.

This company develops AI-powered tools for drug discovery and medicinal chemistry, focusing on the early phases of drug development. Their platform offers molecular space search, property prediction, and interactive visualization to accelerate the identification and optimization of drug candidates.

Cytocast provides a digital twin platform for simulating molecular interactions within human cells to predict drug efficacy and side effects. By integrating multi-omics and patient-specific data, the platform accelerates drug discovery and development by enabling _in silico_ testing and personalized medicine insights.

SyntheticGestalt develops machine learning models specifically designed for drug discovery, enabling researchers to identify potential drug candidates more efficiently. Their software automates various research processes, reducing time and costs associated with traditional drug development methods.

Molecule.one develops AI-driven software for custom organic synthesis, utilizing deep learning and a high-throughput laboratory to synthesize complex compounds in as little as two weeks. The platform addresses the challenge of accessing difficult-to-synthesize molecules, enabling pharmaceutical and chemical industries to efficiently obtain diverse compounds on a success-fee basis.

Molab is a biotechnology research company that utilizes an end-to-end discovery platform combining in-silico design, AI/ML methods, and wet lab validation to optimize small molecule drug development. Their technology accelerates hit-to-lead and lead optimization projects by 1.5 to 2 times through proven ADMET predictions and generative molecular design, addressing the inefficiencies in traditional drug discovery processes.

Uses spatial proteomics combined with advanced microscopy, machine vision, and AI to map molecular interactions within biological samples at unprecedented resolution. This technology enables the identification of novel therapeutic targets and accelerates drug discovery, addressing the limitations of traditional methods in understanding complex disease mechanisms.

This startup develops AI solutions for life sciences, specializing in drug discovery. Their technology designs, conducts, and troubleshoots tasks to accelerate new medication development.

Etcembly utilizes AI-driven protein language models to design and optimize T-cell receptors (TCRs) and antibodies, significantly enhancing the precision and safety of immunotherapy candidates for cancer treatment. The startup addresses the urgent need for faster drug discovery by leveraging extensive immune repertoire databases and advanced sequencing technologies to identify novel therapeutic targets.